Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Sekhri R, Sadjadian P, Becker T, Kolatzki V, Huenerbein K, Meixner R, Marchi H, Wallmann R, Fuchs C, Griesshammer M, Wille K (2021)
Annals of Hematology 100(11): 2707-2716.

Zeitschriftenaufsatz | E-Veröff. vor dem Druck | Englisch
 
Download
OA 1.41 MB
Autor*in
Sekhri, Rohit; Sadjadian, Parvis; Becker, Tatjana; Kolatzki, Vera; Huenerbein, Karlo; Meixner, Raphael; Marchi, HannahUniBi ; Wallmann, Rudolf; Fuchs, ChristianeUniBi ; Griesshammer, Martin; Wille, Kai
Abstract / Bemerkung
**Abstract**
Recently, there has been increased concern about a risk of secondary malignancies (SM) occurring in myelofibrosis (MF) patients receiving ruxolitinib (RUX). In polycythemia vera (PV), on the other hand, only limited data on the risk of SM under RUX treatment are available. To investigate the association between RUX therapy in PV and SM, we conducted a retrospective, single-center study that included 289 PV patients. RUX was administered to 32.9% (95/289) of patients for a median treatment duration of 48.0 months (range 1.0–101.6). Within a median follow-up of 97 months (1.0–395.0) after PV diagnosis, 24 SM occurred. Comparing the number of PV patients with RUX-associated SM (n = 10, 41.7%) with the 14 (58.3%) patients who developed SM without RUX, no significant difference (p = 0.34, chi square test) was found. No increased incidences of melanoma, lymphoma, or solid “non-skin” malignancies were observed with RUX (p = 0.31,p = 0.60, andp = 0.63, respectively, chi square test). However, significantly more NMSC occurred in association with RUX treatment (p = 0.03, chi-squared test). The “SM-free survival” was not significantly different by log rank test for all 289 patients (p = 0.65), for the patients (n = 208; 72%) receiving cytoreductive therapy (p = 0.48) or for different therapy sequences (p = 0.074). In multivariate analysis, advanced age at PV diagnosis (HR 1.062 [95% CI 1.028, 1.098]) but not administration of RUX (HR 1.068 [95% CI 0.468, 2.463]) was associated with an increased risk for SM (p = 0.005). According to this retrospective analysis, no increased risk of SM due to RUX treatment could be substantiated for PV.
Erscheinungsjahr
2021
Zeitschriftentitel
Annals of Hematology
Band
100
Ausgabe
11
Seite(n)
2707-2716
ISSN
0939-5555
eISSN
1432-0584
Page URI
https://pub.uni-bielefeld.de/record/2957095

Zitieren

Sekhri R, Sadjadian P, Becker T, et al. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Annals of Hematology. 2021;100(11):2707-2716.
Sekhri, R., Sadjadian, P., Becker, T., Kolatzki, V., Huenerbein, K., Meixner, R., Marchi, H., et al. (2021). Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Annals of Hematology, 100(11), 2707-2716. https://doi.org/10.1007/s00277-021-04647-0
Sekhri, R., Sadjadian, P., Becker, T., Kolatzki, V., Huenerbein, K., Meixner, R., Marchi, H., Wallmann, R., Fuchs, C., Griesshammer, M., et al. (2021). Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Annals of Hematology 100, 2707-2716.
Sekhri, R., et al., 2021. Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Annals of Hematology, 100(11), p 2707-2716.
R. Sekhri, et al., “Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies”, Annals of Hematology, vol. 100, 2021, pp. 2707-2716.
Sekhri, R., Sadjadian, P., Becker, T., Kolatzki, V., Huenerbein, K., Meixner, R., Marchi, H., Wallmann, R., Fuchs, C., Griesshammer, M., Wille, K.: Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies. Annals of Hematology. 100, 2707-2716 (2021).
Sekhri, Rohit, Sadjadian, Parvis, Becker, Tatjana, Kolatzki, Vera, Huenerbein, Karlo, Meixner, Raphael, Marchi, Hannah, Wallmann, Rudolf, Fuchs, Christiane, Griesshammer, Martin, and Wille, Kai. “Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies”. Annals of Hematology 100.11 (2021): 2707-2716.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2021-09-23T17:08:02Z
MD5 Prüfsumme
f01ee7e877775aa16df6c1f01d9c07dd

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 34462786
PubMed | Europe PMC

Suchen in

Google Scholar